BridgeBio leaps on positive Phase II results for infigratinib

7 March 2023

California, USA-based biotech BridgeBio Pharma (Nasdaq: BBIO) yesterday announced positive results from PROPEL2, a Phase II trial of the investigational therapy infigratinib in children with achondroplasia, a genetic condition that slows bone growth, demonstrating potential best-in-class efficacy and a clean safety profile.

Infigratinib is an oral small molecule designed to inhibit FGFR3 and target achondroplasia at its source, noted BridgeBio, whose shares shot up 52% to $16.52 by close of trading on Monday. BridgeBio has a commercialization agreement for infigratinib with Swiss firm Helsinn.

At the highest dose level evaluated to date (Cohort 5, 0.25 mg/kg once daily), the mean increase from baseline in annualized height velocity (AHV) for the 10 children that have had six-month visits was +3.03 cm/yr (p = 0.0022).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK